CY1112871T1 - Μεθοδος κι ενδιαμεσες ενωσεις - Google Patents

Μεθοδος κι ενδιαμεσες ενωσεις

Info

Publication number
CY1112871T1
CY1112871T1 CY20121100548T CY121100548T CY1112871T1 CY 1112871 T1 CY1112871 T1 CY 1112871T1 CY 20121100548 T CY20121100548 T CY 20121100548T CY 121100548 T CY121100548 T CY 121100548T CY 1112871 T1 CY1112871 T1 CY 1112871T1
Authority
CY
Cyprus
Prior art keywords
unions
preparation
derivatives
intermediates
matanthinoid
Prior art date
Application number
CY20121100548T
Other languages
English (en)
Inventor
Ann M Eldridge
Johann Hiebl
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1112871T1 publication Critical patent/CY1112871T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Μέθοδοι παρασκευής παραγώγων Ν-μεθυλο-L-αλανίνης και νέες ενδιάμεσες ενώσεις της μεθόδου. Τα παράγωγα και οι ενδιάμεσες ενώσεις είναι χρήσιμα για την παρασκευή συμπλεγμάτων μέσου κυτταρικής σύνδεσης/μαιτανσινοειδών.
CY20121100548T 2000-09-12 2012-06-15 Μεθοδος κι ενδιαμεσες ενωσεις CY1112871T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23178400P 2000-09-12 2000-09-12
EP01975197A EP1322597B1 (en) 2000-09-12 2001-09-12 Process and intermediates

Publications (1)

Publication Number Publication Date
CY1112871T1 true CY1112871T1 (el) 2016-04-13

Family

ID=22870636

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100548T CY1112871T1 (el) 2000-09-12 2012-06-15 Μεθοδος κι ενδιαμεσες ενωσεις

Country Status (11)

Country Link
US (2) US6570024B2 (el)
EP (1) EP1322597B1 (el)
JP (1) JP4886961B2 (el)
AR (1) AR030612A1 (el)
AT (1) ATE555078T1 (el)
AU (1) AU2001294549A1 (el)
CY (1) CY1112871T1 (el)
DK (1) DK1322597T3 (el)
ES (1) ES2383792T3 (el)
PT (1) PT1322597E (el)
WO (1) WO2002022554A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
PT1819359E (pt) * 2004-12-09 2015-05-28 Janssen Biotech Inc Imunoconjugados anti-integrina, métodos para a sua produção e sua utilização
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
EP2188311B1 (en) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
KR101763808B1 (ko) 2009-06-04 2017-08-16 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
KR20120123299A (ko) 2009-12-04 2012-11-08 제넨테크, 인크. 다중특이적 항체, 항체 유사체, 조성물 및 방법
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
LT3415531T (lt) 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
PT3956332T (pt) * 2019-04-18 2023-04-24 Indena Spa Processo diasterosselectivo para a preparação de ésteres de maitansinoides contendo tiol ou dissulfeto e seus intermediários
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS61112042A (ja) * 1985-07-31 1986-05-30 Wakunaga Seiyaku Kk 架橋試薬として適当な化合物
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3408158B2 (ja) * 1998-07-17 2003-05-19 大日本製薬株式会社 スルトプリド誘導体及び抗スルトプリド抗体
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
US20040014980A1 (en) 2004-01-22
US6570024B2 (en) 2003-05-27
JP2004509094A (ja) 2004-03-25
EP1322597A4 (en) 2005-10-19
EP1322597B1 (en) 2012-04-25
EP1322597A1 (en) 2003-07-02
WO2002022554A1 (en) 2002-03-21
US6884874B2 (en) 2005-04-26
ATE555078T1 (de) 2012-05-15
AU2001294549A1 (en) 2002-03-26
PT1322597E (pt) 2012-06-01
US20020156318A1 (en) 2002-10-24
DK1322597T3 (da) 2012-07-02
JP4886961B2 (ja) 2012-02-29
ES2383792T3 (es) 2012-06-26
AR030612A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
CY1112871T1 (el) Μεθοδος κι ενδιαμεσες ενωσεις
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
CY1109160T1 (el) Πυρiδinοamiνες ως ρυθμιστες αγγειογενεσης
ATE264863T1 (de) 28-epirapaloge
CY1110000T1 (el) Ενωσεις οκταϋδροβενζιμιδαζολονης ως αναλγητικα
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
NO20054715L (no) Fremgangsmater og mellomprodukter for fremstilling av anti-cancer forbindelser
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
IS2215B (is) Setnar fenýlafleiður, framleiðsla þeirra og notkun
DK1412317T3 (da) Retinoidderivater med antiangiogenetisk-, antitumor og pro-apoptotisk virkning
DE60122216D1 (de) Zolpidem Hemitartrat Solvat
NO20051393L (no) Prosess og intermediater for fremstilling av tienopyrrol-derivater
CY1108300T1 (el) Παρασκευασματα ευγενων μεταλλων και παρασκευασματα λουστρων για την αμεση και εμμεση μεταξοτυπια
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
IS2174B (is) Setnar fenýl-píperasín afleiður, framleiðsla þeirra og notkun
NO20021124L (no) Fremgangsmåte for fremstilling av benzoksazinderivater og mellomprodukter derfor
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
IL154776A0 (en) Method for the preparation of 21-hydroxy-6, 19-oxidoprogesterone and derivatives thereof
IS4980A (is) Aðferðir og milliefni við framleiðslu á setnum krómanól afleiðum
PT1307436E (pt) Processo para a preparacao de derivados de bacatina iii
CY1106306T1 (el) Παραγωγα 5-ιμινο-13-δεοξυ ανθρακυκλινης, οι χρησεις τους και διepγασιες παρασκευης αυτων
DE60044804D1 (de) Acylderivate des 4-demethylpenclomedins, verwendung und zubereitung derselben
AUPR957001A0 (en) Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
DE69627184D1 (de) 3-aminoethyl-n-amidino-2,5-dihydropyrrol derivative mit arginine-mimetischen eigenschaften